Search

Displaying results 531 - 540 of 9347 in total
  1. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    [A228423] Research into the action of hyoscyamine in published literature dates back to 1826. … Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine].[A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.

    Mixtures: Urimar-T, Urimar-T
  2. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    In a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129]. … It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical

  3. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine

    Mixtures: Re-PB Hyos, Re-PB Hyos
  4. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. … A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane

    Mixtures: TL-Care DHA, Se-Plete DHA
  5. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … approval for the treatment of mTNBC patients who have undergone two or more prior therapies.

  6. Drug

    Masitinib

    go.drugbank.com/drugs/DB11526
    InvestigationalVet approved

    Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. … In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

  7. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.

  8. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination … With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).

  9. Drug

    Carfentanil

    go.drugbank.com/drugs/DB01535
    IllicitInvestigationalVet approved

    Carfentanil or carfentanyl (Wildnil) is an analogue of the popular synthetic opioid analgesic fentanyl, and is one of the most potent opioids known (also the most potent opioid used commercially). … Currently sufentanil, approximately 10–20 times less potent (500 to 1000 times the efficacy of morphine per weight) than carfentanil, is the maximum strength fentanyl analog for use in humans.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Ibuprofen

    go.drugbank.com/drugs/DB01050
    ApprovedInvestigational

    Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. … [A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.

    Mixtures: Meds on the Go, Doc in the Box All Day SupplyProducts: DOLIFOR- T 400 MG, DOLIFOR - T CAPSULAS